FDA approves Stivarga for advanced gastrointestinal stromal tumors
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and that no longer respond to other FDA-approved treatments for this disease.
